Home >Current Issue
Volume: 9, Issue: 5, May, 2019
Formulation and pharmacopoeial quality evaluation of ketorolac tromethamine IR tablet and comparison with marketed productAuthor Affiliations
This study describes the formulation of immediate release Ketorolac tromethamine (KT) 10-mg tablet by direct compression method; evaluation of their compliance to various Pharmacopoeial quality parameters, i.e., weight variation, friability, hardness, thickness, moisture content, disintegration, assay, and dissolution; and their comparison with marketed brands for determination of pharmaceutical equivalency. Five formulations of KT were prepared (coded as FKT1, FKT2, FKT3, FKT4, and FKT5) by direct compression method using different superdisintegrants. Micrometric properties of the mixtures of the drug and the excipients prepared for formulation were evaluated. Quality evaluation of the five different formulations and randomly selected four different brands of KT 10-mg tablets purchased from the local market (coded as LKT1, MKT2, MKT3, and SKT4) were performed according to Pharmacopoeia. The results were obtained by UV-Vis spectrophotometer and all the dissolution profiles were characterized by the zero-order kinetics. All the brands of KT and developed formulations met the official specification except SKT4 which showed excessive moisture content of 7.18%. None of the tested brands of KT were found to be pharmaceutically equivalent, whereas two developed formulation were pharmaceutically equivalent with the in house benchmark (MKT2) from which their interchangeability can be suggested.
Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Apurba SA, Nazmul HK, Monjurul K, Nani GB, Khandoker SM, Jamaluddin ATM, Zakiur R. In vitro evaluation of the pharmaceutical equivalence of phenoxymethyl penicillin tablet formulations available in Bangladesh. J Pharm Res, 2011; 4(5):1445-7.
Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL (eds.). The theory and practice of industrial pharmacy. 3rd edition, Lea and Febiger, Philadelphia, PA, pp. 296-300, 2009.
Beyer T, Day GM, Price SL. The prediction, morphology and mechanical properties of the polymorphs of Paracetamol. J Am Chem Soc, 2001; 123:5086-94. https://doi.org/10.1021/ja0102787
British Pharmacopeia. H.M. Stationery office. Appendix IXE, London, UK, vol. 5, p. A285, 2012a.
British Pharmacopeia. H.M. Stationery office. Appendix XIIA, London, UK, vol. 5, p. A320, 2012b.
British Pharmacopeia. H.M. Stationery office. Appendix XIIC, London, UK, vol. 5, p. A341, 2012c.
British Pharmacopeia. H.M. Stationery office. Appendix XVIIG, London, UK, vol. 5, p. A471, 2012d.
British Pharmacopeia. H.M. Stationery office. Appendix XVIIH, London, UK, vol. 5, p. A472, 2012e.
Chopra D, Sinha VR, Singh M. Thermal and isothermal methods in development of sustained release dosage forms of Ketorolac Tromethamine. E-J Chem, 2008; 5(2):316-22. https://doi.org/10.1155/2008/354036
Gohel MC. A review of co-processed directly compressible excipients. J Pharm Sci, 2005; 8(1):76-93.
Halbert GW. Pharmaceutical development. In: Griffin JP, Grady JO, Wells FO (eds.). The text book of pharmaceutical medicine. Greystone Books Ltd., Antrim, Northern Ireland, pp. 39-40, 1993.
Ibrahim YK, Olurinola PF. Comparative microbial contamination levels in wet granulation and direct compression methods of tablet production. Pharm Acta Helv, 1991; 66:293-301.
Mohamed MI, Soliman NA, Rahim SHAE, Development of a novel Ketorolac Tromethaminesublingual film. J Am Sci, 2015; 11(7):27- 37.
Mubengayi CK, Ramli Y, Routaboul C, Gilard V, Karbane ME, Cherrah Y, Martinao MM, Essasi EM. Quality evaluation of Diclofenacformulations manufactured in DR Congo. Pharm Anal Chem Open Access, 2016; 2:112. https://doi.org/10.4172/2471-2698.1000112
Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence-based update on Nonsteroidal anti-inflammatory drugs. Clin Med Res, 2007; 5(1):19-34. https://doi.org/10.3121/cmr.2007.698
Shrivastava A, Gupta VB. Methods for the determination of limit of detection and limit of quantitation of the analytical methods. Chron Young Sci, 2011; 2:21-5. https://doi.org/10.4103/2229-5186.79345
The Pharmaceutical Codex. Principle and practice of pharmaceutics. 12th edition, Pharmaceutical Press, London, UK, pp. 987- 92, 1994.
United States Pharmacopeia and National Formulary (USP 29- NF 24). United States Pharmacopeia Convention, Rockville, MD, p. 2638, 2006a.
United States Pharmacopeia and National Formulary (USP 29- NF 24). United States Pharmacopeia Convention, Rockville, MD, p. 3017, 2006b.
Yasmeen R, Shoaib MH, Khalid H. Comparative study of different formulations of Atenolol. Pak J Pharm Sci, 2005; 18(1):49.
Zhang Y, Law Y, Chakrabarti S. Physical properties and compact analysis of commonly used direct compression binders. AAPS PharmSciTech, 2003; 4(4):489-99. https://doi.org/10.1208/pt040462